Tiger Brokers

Astrazeneca Might Face Questions About Next Year's Profitability

Dow Jones
Jun 30

1428 GMT - AstraZeneca might have to address questions about its potential to expand profitability next year when it reports second-quarter results, Bank of America analysts say in a research note. The U.K. drugmaker is expected to report quarterly sales of $15.4 billion and core earnings per share of $2.51, according to Bank of America. AstraZeneca is likely to reiterate guidance for 2026, but the debate about its 2027 profit margin might kick off again, the analysts says. Consensus expectations point to a 160 basis-point expansion in AstraZeneca's core operating profit margin, but Bank of America is more cautious even if its sales estimate is above consensus, the analysts add. Shares fall 0.6%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 30, 2026 10:29 ET (14:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10